Gilead’s $7.8B Arcellx Acquisition: Scaling CAR-T Oncology Dominance

Gilead Sciences will acquire Arcellx for up to $7.8 billion, enhancing its CAR-T oncology portfolio with a focus on multiple myeloma. The acquisition centers on anito-cel, a CAR-T therapy awaiting FDA approval, with the deal signaling Gilead's strategic push into oncology growth.

Listen